AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24908205 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy
Number of subjects: 255
Study 23206205 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV stereotypes
Number of subjects: 93
Study 23206205 — intervention group
Group type: COMPARATOR
Intervention: Prejudice
Number of subjects: 93
Study 23206205 — intervention group
Group type: COMPARATOR
Intervention: Discrimination
Number of subjects: 93
Study 23206205 — intervention group
Group type: COMPARATOR
Intervention: Objective HIV risk
Number of subjects: 93
Study 20480055 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminalia chebula extract rinse
Number of subjects: 30
Study 20480055 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 30
Study 18278400 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Number of subjects: 48
Study 18278400 — intervention group
Group type: COMPARATOR
Intervention: Infrared photocoagulation
Number of subjects: 48
Study 15647412 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa, 40,000 IU/wk
Number of subjects: 48
Study 12901592 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinrix vaccine (0‐, 1‐, 6‐month vaccination schedule)
Number of subjects: 264
Study 11051122 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 1500 mg twice daily (monotherapy)
Number of subjects: 286
Study 11051122 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 1500 mg twice daily (add-on phase)
Number of subjects: 286
Study 11051122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 11051122 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 3000 mg/d (add-on phase)
Number of subjects: 286
Study 8619442 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine B
Number of subjects: 39
Study 8619442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8619442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 1416842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 287
Study 1416842 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil
Number of subjects: 287
Study 4020974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory surgery (group 1)
Number of subjects: 54
Study 4020974 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative management (group 2)
Number of subjects: 54
Study 4020974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory surgery (group 3)
Number of subjects: 54
Study 31770221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy and/or salpingectomy
Number of subjects: 238436
Study 31770221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy and salpingectomy
Number of subjects: 238436
Study 31770221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 238436
Study 31770221 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Number of subjects: 238436
Study 31770221 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomies
Number of subjects: 238436
Study 31770221 — intervention group
Group type: COMPARATOR
Intervention: Comparison cohort (no surgeries)
Number of subjects: 238436
Study 30089663 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive low-glucose suspend (PLGS) using Tandem Diabetes Care t:slim X2 pump with Basal‐IQ and Dexcom G5 sensor
Number of subjects: 103
Study 30089663 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 103
Study 26797931 — intervention group
Group type: COMPARATOR
Intervention: Pregnenolone pretreatment
Number of subjects: 0
Study 26797931 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 0
Study 23913917 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 2076
Study 23913917 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered, computer-assisted self-management
Number of subjects: 2076
Study 23913917 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered program with enhanced social support
Number of subjects: 2076
Study 22443839 — intervention group
Group type: EXPERIMENTAL
Intervention: Short family intervention with five weekly home‐based intervention sessions
Number of subjects: 151
Study 20646413 — intervention group
Group type: EXPERIMENTAL
Intervention: uNGAL
Number of subjects: 92
Study 20646413 — intervention group
Group type: EXPERIMENTAL
Intervention: uIL-18
Number of subjects: 92
Study 20646413 — intervention group
Group type: EXPERIMENTAL
Intervention: SCr
Number of subjects: 92
Study 17968918 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 120
Study 17968918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15764620 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 0
Study 15764620 — intervention group
Group type: COMPARATOR
Intervention: LDL-C
Number of subjects: 0
Study 12032011 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 microg/kg
Number of subjects: 80
Study 12032011 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg/kg
Number of subjects: 80
Study 12032011 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1 to 5 microg/kg)
Number of subjects: 80
Study 11783181 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinmaitong composita (JMTC)
Number of subjects: 66
Study 11783181 — intervention group
Group type: COMPARATOR
Intervention: Jinkui Shenqi (JKSQ)
Number of subjects: 66
Study 8907403 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led drug prevention program
Number of subjects: 0
Study 8907403 — intervention group
Group type: COMPARATOR
Intervention: Adult-led drug prevention program
Number of subjects: 0
Study 8907403 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 0
Study 2350832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiao‐Zhi‐Tang (TZT)
Number of subjects: 68
Study 2350832 — intervention group
Group type: COMPARATOR
Intervention: Inositol and Mai Tong
Number of subjects: 68
Study 573558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine mixed with chloroprocaine (0.5 mg bupivacaine and 3 mg chloroprocaine)
Number of subjects: 20
Study 573558 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (0.5 mg)
Number of subjects: 20
Study 573558 — intervention group
Group type: COMPARATOR
Intervention: Chloroprocaine alone (3 mg)
Number of subjects: 20
Study 31499231 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) intervention
Number of subjects: 243
Study 31499231 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 243
Study 29233143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 192
Study 29233143 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 192
Study 25486290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day)
Number of subjects: 73
Study 25486290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 24666268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 36
Study 24666268 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36
Study 24666268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24666268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine and Methylphenidate
Number of subjects: 36
Study 22511483 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone metacarpophalangeal joint arthroplasty (SMPA)
Number of subjects: 162
Study 22511483 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical control
Number of subjects: 162
Study 19346430 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibition (ACEI)
Number of subjects: 85
Study 19346430 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study 17617751 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 82
Study 17617751 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 15118828 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior spondylodesis
Number of subjects: 22
Study 15118828 — intervention group
Group type: COMPARATOR
Intervention: Anteroposterior spondylodesis
Number of subjects: 22
Study 11939682 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin-tazobactam
Number of subjects: 98
Study 11939682 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin-tazobactam
Number of subjects: 98
Study 9808683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg twice daily
Number of subjects: 20
Study 9808683 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 300 mg three times daily
Number of subjects: 20
Study 7663594 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic recording during mechanical ventilation
Number of subjects: 44
Study 7663594 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic recording during spontaneous breathing
Number of subjects: 44
Study 7663594 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified) during mechanical ventilation
Number of subjects: 44
Study 7663594 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified) during spontaneous breathing
Number of subjects: 44
Study 2803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion
Number of subjects: 10
Study 2803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine after volume expansion
Number of subjects: 10
Study 2803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine alone
Number of subjects: 10
Study 2803986 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine before volume expansion
Number of subjects: 10
Study 7447770 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day 0.25% timolol ophthalmic solution
Number of subjects: 41
Study 7447770 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day 0.25% timolol ophthalmic solution
Number of subjects: 41
Study 31530612 — intervention group
Group type: EXPERIMENTAL
Intervention: Team monitoring (clinical team monitoring with nursing outreach)
Number of subjects: 2750
Study 31530612 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced feedback (real-time feedback to patients about expected symptom severity)
Number of subjects: 2750
Study 31530612 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced feedback
Number of subjects: 2750
Study 27956003 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Number of subjects: 459
Study 27956003 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 25 mg
Number of subjects: 459
Study 27956003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 25284089 — intervention group
Group type: EXPERIMENTAL
Intervention: elosulfase alfa 2.0mg/kg/week
Number of subjects: 176
Study 25284089 — intervention group
Group type: COMPARATOR
Intervention: elosulfase alfa 2.0mg/kg/every other week
Number of subjects: 176
Study 25284089 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 176
Study 23663521 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred proactive telephone support (daily for up to 14 days after hospital discharge)
Number of subjects: 1116
Study 23663521 — intervention group
Group type: COMPARATOR
Intervention: Person-centred reactive support (mothers can phone the support team up to day 14 after hospital discharge)
Number of subjects: 1116
Study 21864719 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease self-management support (CDSMS) using the Flinders Program for 6 months
Number of subjects: 252
Study 21864719 — intervention group
Group type: COMPARATOR
Intervention: Attention control intervention (health information only) for 6 months
Number of subjects: 252
Study 19762175 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation to offer a pacifier
Number of subjects: 0
Study 19762175 — intervention group
Group type: COMPARATOR
Intervention: Control (no pacifier recommendation)
Number of subjects: 0
Study 17881285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile and internet intervention (SMS and website diary)
Number of subjects: 34
Study 17881285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 15140339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 15 mg
Number of subjects: 1000
Study 15140339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 30 mg
Number of subjects: 1000
Study 15140339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 45 mg
Number of subjects: 1000
Study 15140339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 15 mg plus Sulfonylurea (SU)
Number of subjects: 1000
Study 15140339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 30 mg plus Sulfonylurea (SU)
Number of subjects: 1000
Study 15140339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 30 mg plus Metformin (MET)
Number of subjects: 1000
Study 11598535 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2 low dose
Number of subjects: 33
Study 11598535 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2 high dose
Number of subjects: 33
Study 11598535 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU weekly
Number of subjects: 33
Study 11598535 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomudex(R)
Number of subjects: 33
Study 11598535 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 5FU
Number of subjects: 33
Study 9291217 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician advice against tobacco use
Number of subjects: 13923
Study 9291217 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 13923
Study 9291217 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority status
Number of subjects: 13923
Study 9291217 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in other risk practices
Number of subjects: 13923
Study 8296582 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (400 mg daily)
Number of subjects: 34
Study 8296582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8296582 — intervention group
Group type: EXPERIMENTAL
Intervention: Open moclobemide
Number of subjects: 34
Study 8296582 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 34
Study 8296582 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide and Placebo
Number of subjects: 34
Study 3719424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25% solution, 25 mg first dose, 10 ml, reinjections every hour for 10 mg)
Number of subjects: 103
Study 3719424 — intervention group
Group type: COMPARATOR
Intervention: 2-Chloroprocaine (2% solution, 200 mg first dose, 10 ml, reinjections every 30 min for 80 mg)
Number of subjects: 103
Study 11454179 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha/amantadine sulphate
Number of subjects: 55
Study 11454179 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha/placebo
Number of subjects: 55
Study 11454179 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha
Number of subjects: 55
Study 31218738 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention to improve OAC prescription
Number of subjects: 246
Study 31218738 — intervention group
Group type: COMPARATOR
Intervention: Current clinical practice (Control)
Number of subjects: 246
Study 31218738 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriately prescribed OACs
Number of subjects: 246
Study 31218738 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriately not prescribed OACs
Number of subjects: 246
Study 31218738 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription of OACs at admission
Number of subjects: 246
Study 29474843 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel staples
Number of subjects: 242
Study 29474843 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 242
Study 27460100 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (40 mg pantoprazole plus 1 g amoxicillin twice a day for 5 days, then 40 mg pantoprazole and 500 mg clarithromycin twice a day and 500 mg metronidazole three times a day for 5 days)
Number of subjects: 390
Study 27460100 — intervention group
Group type: COMPARATOR
Intervention: 14-day modified bismuth quadruple therapy (40 mg pantoprazole, 600 mg bismuth subcitrate, 1 g tetracycline, and 1 g amoxicillin, twice a day)
Number of subjects: 390
Study 27460100 — intervention group
Group type: COMPARATOR
Intervention: Modified bismuth quadruple therapy
Number of subjects: 390
Study 24392946 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly 56.5 μg teriparatide
Number of subjects: 237
Study 24392946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 22569710 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP + GnRH agonist
Number of subjects: 300
Study 22569710 — intervention group
Group type: COMPARATOR
Intervention: OCP + GnRH antagonist
Number of subjects: 300
Study 20332770 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg once daily for 28 days
Number of subjects: 48
Study 20332770 — intervention group
Group type: COMPARATOR
Intervention: placebo once daily for 28 days
Number of subjects: 48
Study 17383926 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BoNT) injections into the submandibular glands
Number of subjects: 0
Study 17383926 — intervention group
Group type: COMPARATOR
Intervention: Botulinum neurotoxin (BoNT) injections into the parotid glands
Number of subjects: 0
Study 17383926 — intervention group
Group type: COMPARATOR
Intervention: Comparison between submandibular and parotid injections
Number of subjects: 0
Study 15709833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 15709833 — intervention group
Group type: COMPARATOR
Intervention: Other forms of treatment (pharmacotherapy either alone or in combination with family therapy)
Number of subjects: 0
Study 12116726 — intervention group
Group type: COMPARATOR
Intervention: 0.28% triclosan/5% pyrophosphate/0.145% sodium fluoride, 0.2% triclosan/0.5% zinc citrate/0.112% sodium fluoride, 0.145% sodium fluoride and 0.15% sodium monofluorophosphate (applied neat and undiluted via a performed tooth shield)
Number of subjects: 185
Study 12116726 — intervention group
Group type: COMPARATOR
Intervention: 0.28% triclosan/5% pyrophosphate/0.243% sodium fluoride, 0.3% triclosan/2% Gantrez copolymer/0.24% sodium fluoride (1:3 aqueous slurry rinses)
Number of subjects: 185
Study 12116726 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine, 0.045% triclosan in ethanol plus respective vehicle placebos (mouthrinses)
Number of subjects: 185
Study 10422923 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion
Number of subjects: 56
Study 10422923 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral block
Number of subjects: 56
Study 10422923 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled morphine
Number of subjects: 56
Study 7766565 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g raw potato starch (550 g RS/kg)
Number of subjects: 10
Study 7766565 — intervention group
Group type: COMPARATOR
Intervention: 50 g pregelatinized potato starch (0 g RS/kg)
Number of subjects: 10
Study 7766565 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g pregelatinized potato starch plus 20 g lactulose (670 g indigestible disaccharide/kg)
Number of subjects: 10
Study 2288551 — intervention group
Group type: EXPERIMENTAL
Intervention: VT = 12 ml/kg (group 1)
Number of subjects: 103
Study 2288551 — intervention group
Group type: COMPARATOR
Intervention: VT = 6 ml/kg (group 2)
Number of subjects: 103
Study 6969109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin prophylaxis administered intraoperatively
Number of subjects: 3
Study 6969109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin prophylaxis administered both intraoperatively and postoperatively
Number of subjects: 3
Study 6969109 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3
Study 31993637 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives of €350 for 12-month continuous smoking abstinence
Number of subjects: 604
Study 31203212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg every 2 weeks)
Number of subjects: 128
Study 31203212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 31417058 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily dose of ferrous sulphate (65 mg elemental iron)
Number of subjects: 182
Study 31417058 — intervention group
Group type: COMPARATOR
Intervention: Twice daily dose of ferrous sulphate (130 mg elemental iron)
Number of subjects: 182
Study 28524699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine CR (80 mg)/candesartan (8 mg)
Number of subjects: 51
Study 28524699 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg)/candesartan (8 mg)
Number of subjects: 51
Study 26563714 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting (EVH)
Number of subjects: 228
Study 26563714 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvesting (OVH)
Number of subjects: 228
Study 23983995 — intervention group
Group type: EXPERIMENTAL
Intervention: High Frequency Positive Pressure Mechanical Ventilation (HFPPV)
Number of subjects: 0
Study 20925019 — intervention group
Group type: COMPARATOR
Intervention: Chenodesoxycholic acid (CDCA)
Number of subjects: 12
Study 20925019 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg for 6 days)
Number of subjects: 12
Study 19951216 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified red clover (Trifolium pratense) isoflavone (86 mg/day) tablets
Number of subjects: 23
Study 19951216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17294808 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine tablets (two brands)
Number of subjects: 20